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Abstract
Herein, we describe the establishment and characterization of the first mixed-phenotype acute leukemia cell
line (JIH-5). The JIH-5 cell line was established from leukemia cells with B lymphoid/myeloid phenotype
from a female mixed-phenotype acute leukemia patient. JIH-5 cells exhibit an immunophenotype comprised
of myeloid and B lymphoid antigens. Whole-exome sequencing revealed somatic mutations in nine genes
in JIH-5 cells. Transcriptional sequencing of JIH-5 cells identified EP300-ZNF384 fusion transcript, which is a
recurrent alteration in B cell acute lymphoblastic leukemia. Our results suggest that the JIH-5 cell line may
serve as a tool for the study of mixed-phenotype acute leukemia or EP300-ZNF384.
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Findings
In a minority of patients with acute leukemia, it is
difficult to determine the lineage origin because of
the expression of both lymphoid and myeloid lineage-
specific antigens [1–5]. The 2008 World Health
Organization (WHO) classification introduced a new
designation for this entity, mixed-phenotype acute
leukemia (MPAL) [6]. Tumor cells are characterized
by various biomarkers, such as cytogenetic, molecular
genetic, or epigenetic aberrations [7–11]. However,
the pathogenesis and optimal therapy of patients with
MPAL remain largely undefined. Although several
leukemia cell lines were once reported as BAL cell
lines [12–17], none fulfill the WHO 2008 criteria for
MPAL. So far, no cell line established from patients
with MPAL has been reported. Recently, we established
the first human MPAL cell line, JIH-5. Herein, we
present the phenotypic, genetic, and functional proper-
ties of JIH-5 cells. We applied next-generation sequen-
cing (NGS) technology to unravel the transcriptome of
JIH-5 cells.
A 21-year-old female with MPAL was admitted to
our hospital in December 2008. Bone marrow sample
was obtained from the patient with informed consent
in December 2009 during the second relapse. Mono-
nuclear cells were cultured in Iscove’s Modified
Dulbecco’s Medium with 20 % fetal calf serum. The
leukemia cells exhibited gradual cell proliferation
2 months after primary culture was initiated. The
cell line was designated JIH-5. JIH-5 cells were toler-
ant to freezing in defined medium, storage in liquid
nitrogen, thawing, and subsequent expansion. JIH-5
cells grow as single cells in suspension culture.
JIH-5 cells exhibit medium-sized spheroidal mor-
phologies and large round nuclei with fine nuclear
chromatin (Fig. 1a). The immunoprofiles of the JIH-
5 cells are summarized in Table 1. JIH-5 cells ex-
press typical antigens of myeloid lineages (CD13,
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CD15, CD33, and cMPO), as well as antigens of B
lymphoid lineages (CD10, CD19, CD22, CD23, and
cCD79a) (Fig. 1b). The negative polymerase chain
reaction (PCR) results with EBV and mycoplasma
specific primers excluded EBV and mycoplasma con-
tamination. The colony formation rate of JIH-5 cells
was 1.41 % by semi-solid methylcellulose clonogenic
assay. Tumor masses were found in one of six mice
injected with JIH-5 cells after 83 days. The genetic
identity of JIH-5 cells was compared to BM cell sam-
ple from the patient using short tandem repeat PCR.
The results of authentication analysis indicated that
the JIH-5 cells remained genetically identical to the
founding tumor cells.
Fig. 1 Morphological and immunophenotypic analysis of JIH-5. a. Morphology of SHI-1 cells on Wright’s staining under a light microscopy (original
magnification ×1000). b. Immunophenotypic features of JIH-5 cells
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Combined G-banding and spectral karyotype (SKY)




der(17)t(17;17)(p13;q22),del(19)(q13) (Fig. 2a, b). A total
of ten copy number alterations (CNA) were detected by a-
CGH. Both fluorescence in situ hybridization (FISH) and a-
CGH analysis showed a microdeletion affecting ETV6 gene
(Fig. 2c, d). No mutations were detected in 15 acute
leukemia-related genes by direct sequencing of PCR prod-
ucts in JIH-5 cells. The global expression profile of JIH-5
was compared to leukemic blast cells from the patient, and
a range of cell lines representing B and Tcell acute lympho-
blastic leukemia (T-ALL). The results indicate that tran-
scriptionally, JIH-5 cells more closely resemble cell lines of
B rather than T-ALL origin.
We captured and sequenced exomes from the paired
sample of JIH-5 cells and control specimen in remission.
We detected somatic tumor-specific mutations in a total
of nine genes (eight missense and one nonsense muta-
tions), including ABCA8, BCHE, CALCA, CSTF2,
FPR1, KCNJ8, MAFB, STMN1, and TAAR8; all were
heterozygous in JIH-5 cells. Bioinformatic evaluation of
the transcriptional sequencing data and RT-PCR verifi-
cation revealed six novel fusions, comprising three act-
ing as translocations: EP300 (at 22q13) with both the
adjacent ZNF384 and CHD4 (12p13), MSH2 (2p21)
with NLK (17q11), and three microdeletions, HACL1-
COLQ (3p25), HDAC8-CITED1 (Xq13), and POLA2-
CDC42EP2 (11q13). Interestingly, the EP300 gene was
found to fuse simultaneously with two partner genes lo-
cated in 12p13, CHD4, and ZNF384 (Fig. 3a). Further
FISH analysis with BAC and fosmid clones flanking
EP300, CHD4, and ZNF384 confirmed breakpoints
within CHD4 and EP300 due to a complex, apparently
insertional, rearrangement involving 12p13 and 22q13
(Fig. 3b). Mutations of EP300 have been detected in
Rubinstein-Taybi syndrome and some solid tumors [18–
22]. The EP300 was found to be fused with MLL in an
AML patient harboring t(11;22)(q23;q13) [23]. CHD4
encodes a catalytic subunit of the NuRD complex and
plays an important role in transcriptional regulation,
chromatin assembly, and DNA damage repair [24]. The
ZNF384 gene has been observed recurrently fused with
EWSR1, TAF15, or E2A in acute leukemia [25, 26]. Re-
cently, the EP300-ZNF384 was identified as a recurrent
aberration in B cell acute lymphoblastic leukemia (B-
ALL) [27]. The genetic abnormalities found in JIH-5
cells are detailed in Table 2.
In summary, we established a novel MPAL cell
line, JIH-5, and characterized its biologic background
comprehensively to show a novel oncogenomic gene
fusion together with an associated cluster of muta-
tions. Our findings suggested that the JIH-5 cell line
may serve as a tool for the study of MPAL or
EP300-ZNF384.
Table 1 Immunophenotypic characterization of the JIH-5 cells
and the primary leukemia cells
Antigen
(CD)
Primary leukemia cells (%) JIH-5 cells (%)
At presentation At the second
relapse
T/NK cell markers
CD2 0.2 0.5 16.4
CD3 ND ND 1.1
CD5 ND ND 1.1
CD7 0.3 0.6 0
CD56 ND ND 1.4
cCD3 ND 0 0.3
B cell markers
CD10 5.6 11.6 34.8
CD19 99.8 93.9 90.4
CD20 0.1 0.5 1.7
CD22 ND ND 73.6
CD23 ND ND 53.3
FMC-7 ND ND 2.1
cCD79a 97.6 93.6 80.8
Myeloid markers
CD13 28.9 72.2 79.2
CD14 0.2 1.0 2.1
CD15 14.1 7.3 4.2
CD33 85.2 80.9 78.6
CD64 ND ND 5.6
MPO 11.9 59.1 66.8
Progenitor markers
CD34 92.5 95.3 13.6
CD38 ND ND 30
CD117 0.1 0.8 3.6
HLA-DR 65.8 11.2 52.2
Adhesion markers
CD11b ND ND 0.9
Erythroid markers
CD71 ND ND 5.3
GPA ND ND 1.3
Megakaryocytic markers
CD41 ND ND 47.2
CD61 ND ND 1.1
Plasma cell markers
CD138 ND ND 1.8
ND not done
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Fig. 2 Cytogenetic analysis of JIH-5. Analysis by SKY (a) and G-banding (b) revealed a complex pseudodiploid karyotype in which 15/46 chromosomes
showed visible rearrangements (arrows). FISH analysis using golden path clones of genes at/near breakpoints identified a microdeletion affecting the
12p13 region encompassing BAC clone RP11-94N22 which bears the ETV6 gene (c). d Image shows array CGH (244 K) analysis in JIH-5 cells revealed a
0.15-Mb deletion (11.80–11.95 Mb) in the ETV6 gene. Cytogenetic harvesting, labeling, and fluorescence microscopy were performed as
described previously
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Fig. 3 Fusion of EP300 (located at 22q13) with both CHD4 and ZNF384 (at 12p13). a Sanger sequencing data confirmed two novel fusion
transcripts involving EP300 gene, involving CHD4 (exon 2) with EP300 (exon 2) and EP300 (exon 6) with ZNF384 (exon 3). b Fusion of EP300
(located at 22q13) with both CHD4 and ZNF384 (at 12p13) appears to have resulted from a complex series of genomic rearrangements as shown
by chromosome painting (left homologues) and FISH (right) using tilepath BAC and fosmid clones (upper panel). Note the presence of two discrete
regions of chr. 12-derived material on the der(22) implying a complex, possibly insertional, event. This picture is supported by FISH revealing
interspersal of chr. 12- and 22-derived BAC clones over circa 9 MBp from 12p13 (lower panel). FISH revealed breakpoints within RP11-1137p19 and
1078o11 involving the ZNF384/CHD4 and EP300 regions implicated in fusion events
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Culture medium IMDM + 20 % FCS
Growth pattern Single cells in suspension




Optimal split 1:3 every 3–4 days
Cryopreservation In 70 % medium, 20 % FCS, 10 % DMSO
Morphology medium-sized spheroidal morphologies
Viral status Negative for EBV
Contamination Negative for mycoplasma
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Somatic mutations in ABCA8, BCHE, CALCA,





Ping et al. Journal of Hematology & Oncology  (2015) 8:100 Page 6 of 7
15. Ariyasu T, Matsuo Y, Harashima A, Nakamura S, Takaba S, Tsubota T, et al.
Establishment and characterization of “biphenotypic” acute leukemia cell
lines with a variant Ph translocation t(9;22;10)(q34;q11;q22). Hum Cell.
1998;11(1):43–50.
16. Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U, et al.
The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal
rearrangement is biphenotypic and responsive to interleukin-7.
Br J Haematol. 1994;86(2):275–83.
17. Tanabe S, Fukuhara S, Yoneda T, Ohmori K, Nosaka T, Hatanaka M, et al.
Characterization of a novel biphenotypic leukemia cell line, TA-1, with
myeloperoxidase and inducible cytoplasmic mu chain: altered
rearrangement patterns of antigen receptor genes. Int J Hematol.
1993;57(3):229–43.
18. Zimmermann N, Acosta AM, Kohlhase J, Bartsch O. Confirmation of EP300
gene mutations as a rare cause of Rubinstein-Taybi syndrome. Eur J Hum
Genet. 2007;15(8):837–42.
19. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al.
Mutations truncating the EP300 acetylase in human cancers. Nat Genet.
2000;24(3):300–3.
20. Bryan EJ, Jokubaitis VJ, Chamberlain NL, Baxter SW, Dawson E, Choong DY,
et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas.
Int J Cancer. 2002;102(2):137–41.
21. Koshiishi N, Chong JM, Fukasawa T, Ikeno R, Hayashi Y, Funata N, et al. p300
gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric
Cancer. 2004;7(2):85–90.
22. Kim MS, Lee SH, Yoo NJ, Lee SH. Frameshift mutations of tumor suppressor
gene EP300 in gastric and colorectal cancers with high microsatellite
instability. Hum Pathol. 2013;44(10):2064–70.
23. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, et al.
Adenoviral E1A-associated protein p300 is involved in acute myeloid
leukemia with t(11;22)(q23;q13). Blood. 1997;90(12):4699–704.
24. Musselman CA, Ramírez J, Sims JK, Mansfield RE, Oliver SS, Denu JM, et al.
Bivalent recognition of nucleosomes by the tandem PHD fingers of the
CHD4 ATPase is required for CHD4-mediated repression. Proc Natl Acad Sci
U S A. 2012;109(3):787–92.
25. Zhong CH, Prima V, Liang X, Frye C, McGavran L, Meltesen L, et al. E2A-ZNF384
and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute
leukemia. Leukemia. 2008;22(4):723–9.
26. Martini A, La Starza R, Janssen H, Bilhou-Nabera C, Corveleyn A, Somers R, et
al. Recurrent rearrangement of the Ewing’s sarcoma gene, EWSR1, or its
homologue, TAF15, with the transcription factor CIZ/NMP4 in acute
leukemia. Cancer Res. 2002;62(19):5408–12.
27. Gocho Y, Kiyokawa N, Ichikawa H, Nakabayashi K, Osumi T, Ishibashi T et al.
A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute
lymphoblastic leukemia. Leukemia. 2015 May 6. doi: 10.1038/leu.2015.111.
[Epub ahead of print]
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ping et al. Journal of Hematology & Oncology  (2015) 8:100 Page 7 of 7
